Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating) – Equities research analysts at HC Wainwright issued their Q2 2023 earnings per share (EPS) estimates for Acer Therapeutics in a research report issued to clients and investors on Tuesday, March 28th. HC Wainwright analyst V. Bernardino forecasts that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Acer Therapeutics' current full-year earnings is ($0.23) per share.
Get
Acer Therapeutics alerts:
Acer Therapeutics Stock Up 1.3 %
Acer Therapeutics stock opened at $0.76 on Wednesday. Acer Therapeutics has a 52 week low of $0.65 and a 52 week high of $4.56. The company has a market capitalization of $16.01 million, a price-to-earnings ratio of -0.53 and a beta of 0.65. The stock has a 50-day moving average price of $1.86 and a 200 day moving average price of $1.84.
Institutional Trading of Acer Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC boosted its stake in shares of Acer Therapeutics by 76.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,226,191 shares of the biopharmaceutical company's stock worth $3,078,000 after acquiring an additional 529,653 shares during the last quarter. Knott David M Jr acquired a new stake in shares of Acer Therapeutics in the fourth quarter worth approximately $351,000. Vanguard Group Inc. boosted its stake in shares of Acer Therapeutics by 55.5% in the first quarter. Vanguard Group Inc. now owns 278,215 shares of the biopharmaceutical company's stock worth $807,000 after acquiring an additional 99,335 shares during the last quarter. Meridian Wealth Management LLC acquired a new stake in shares of Acer Therapeutics in the fourth quarter worth approximately $180,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Acer Therapeutics by 216.8% in the second quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company's stock worth $88,000 after acquiring an additional 47,700 shares during the last quarter. 27.96% of the stock is currently owned by hedge funds and other institutional investors.
About Acer Therapeutics
(Get Rating)
Acer Therapeutics, Inc is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases.
See Also
- Get a free copy of the StockNews.com research report on Acer Therapeutics (ACER)
- Dave & Buster's Rebound Could Score for Investors
- Cal-Maine: Is it Time to Chase this Stock Higher?
- The Most Important Warren Buffett Stock for Investors: His Own
- Three Mid Caps Wall Street Sees Doubling Within 12 Months
- It's No Stretch: Lululemon Could Break Out of its Range
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
宏碁治疗股份有限公司(纳斯达克代码:宏碁评级)-宏碁温赖特的股票研究分析师在3月28日星期二发布的一份研究报告中发布了他们对宏碁治疗公司2023年第二季度每股收益(EPS)的估计。HC Wainwright分析师V.Bernardino预测,这家生物制药公司将公布本季度每股收益为0.26美元。HC Wainwright对该股的评级为买入,目标价为12.00美元。对宏碁治疗公司目前全年收益的普遍估计是每股0.23美元。
到达
宏基治疗公司警报:
宏碁治疗类股上涨1.3%
宏碁治疗公司的股票周三开盘报0.76美元。宏基治疗的52周低点为0.65美元,52周高点为4.56美元。该公司市值为1,601万美元,市盈率为-0.53倍,贝塔系数为0.65。该股的50日移动均线价格为1.86美元,200日移动均线价格为1.84美元。
宏基治疗的机构性交易
一些机构投资者和对冲基金最近改变了他们在该业务中的头寸。南塔哈拉资本管理有限责任公司在第四季度增持了宏碁治疗公司76.0%的股份。Nantahala Capital Management LLC在上个季度增持了529,653股后,现在拥有这家生物制药公司价值3,078,000美元的股票1,226,191股。诺特·David M Jr在第四季度收购了宏碁治疗公司价值约351,000美元的新股。先锋集团(Vanguard Group Inc.)在第一季度增持了宏碁治疗公司55.5%的股份。先锋集团(Vanguard Group Inc.)在上个季度增持了99,335股后,目前持有这家生物制药公司278,215股股票,价值80.7万美元。Meridian Wealth Management LLC在第四季度收购了宏碁治疗公司价值约18万美元的新股份。最后,复兴科技有限责任公司在第二季度将其在宏碁治疗公司的股份增加了216.8%。复兴科技有限责任公司现在持有这家生物制药公司6.97万股票,价值8.8万美元,在上个季度额外收购了4.77万股票。27.96%的股票目前由对冲基金和其他机构投资者持有。
宏碁治疗公司简介
(获取评级)
宏碁治疗公司是一家制药公司。从事医疗需求疗法的获取、开发和商业化。其产品线包括宏碁-001 Edsivo和宏碁-2820。Edsivo是一种治疗血管Ehler-Danlos综合征的塞利洛尔。宏碁-001是用于治疗尿素循环障碍和枫糖浆尿液疾病。
另请参阅
- 免费获取StockNews.com关于宏碁治疗(Acer)的研究报告
- Dave&Buster的反弹可能会为投资者带来好处
- 加州缅因州:是时候追逐这只股票了吗?
- 对投资者来说最重要的沃伦·巴菲特股票:他自己的股票
- 华尔街预计三只中型股在12个月内翻一番
- 这是不可伸展的:lululemon可以突破它的范围
接受《宏基治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对宏碁治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。